Body weight, gender and response to TNF-α blockers in axial spondyloarthritis

Elisa Gremese, Simone Bernardi, Sara Bonazza, Marcin Nowik, Giusy Peluso, Alfonso Massara, Barbara Tolusso, Laura Messuti, Maria Concetta Miceli, Angelo Zoli, Francesco Trotta, Marcello Govoni, Gianfranco Ferraccioli

Risultato della ricerca: Contributo in rivistaArticolo in rivista

74 Citazioni (Scopus)


The objective of this study was to determine whether BMI and gender could lead to a different response rate to anti-TNF agents in patients affected by axial SpA. METHODS: One hundred and seventy patients with active axial SpA (defined as a BASDAI ≥ 4) treated with an anti-TNF agent [adalimumab (ADA), etanercept (ETA), infliximab (IFX)] were retrospectively evaluated. Patients were divided according to the baseline BMI as normal weight (BMI < 25), overweight (BMI 25-30) and obese (BMI ≥ 30). After 12 months of treatment a 50% improvement of the initial BASDAI (BASDAI50) was the primary end point and BASDAI ≤ 1 was the secondary end point. RESULTS: After 12 months of anti-TNF treatment, 67.8% of men and 46.2% of women reached the BASDAI50 (P = 0.01). According to BMI categories, the rate of BASDAI50 achievement decreased from 72.8% in normal weight subjects to 54.5% in overweight and 30.4% in obese subjects (P < 0.001). In the logistic regression analysis, the best independent predictors of failure to obtain a BASDAI50 response at the 12th month of therapy in axial SpA patients were female gender [odds ratio (OR) 3.23 (95% CI 1.52, 7.14)] and a BMI ≥ 30 [OR 3.57 (95% CI 1.15, 11.11)]. Analysing outcomes based on IFX therapy (the larger subgroup), the BASDAI50 response rate fell from 79.0% in normal weight subjects to 56.7% in overweight and 16.7% in obese subjects (P < 0.001). No significant differences were observed with ADA and ETA. CONCLUSION: Data suggest that being female, overweight and mostly obese is associated with a lower rate of success in obtaining response status in axial SpA patients treated with anti-TNF drugs. Body weight could represent a modifiable factor to reach the best outcome in axial SpA
Lingua originaleEnglish
pagine (da-a)875-881
Numero di pagine7
Stato di pubblicazionePubblicato - 2014


  • TNF-α blockers
  • axial spondyloarthritis


Entra nei temi di ricerca di 'Body weight, gender and response to TNF-α blockers in axial spondyloarthritis'. Insieme formano una fingerprint unica.

Cita questo